Tuesday, May 13, 2025 5/13/2025

Validation of preclinical assays with clinical data to evaluate the safety of estrogenic botanical dietary supplements

Award Number: F31AT010559
ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

Group Awards By:

View Award Description

Validation of preclinical assays with clinical data to evaluate the safety of estrogenic botanical dietary supplements - ABSTRACT More than half of the top selling botanicals dietary supplements (BDS) are marketed to peri- and post- menopausal women. Approximately 70% of women in this age group reported having consumed BDS to manage symptoms or treat disease. The focus of this project is to address the safety of these popular BDS. We hypothesize that most BDS used by women to manage menopausal symptoms are safe, but some botanicals might pose risk through modulation of estrogen biosynthesis and metabolism. By carrying out post-analyses of urine and serum from our completed Phase I and Phase II clinical trials of black cohosh (Actaea racemosa), hops (Humulus lupulus) and red clover (Trifolium pratense), we will confirm possible modulation to hormone levels. Two in vitro cell assays will be validated to model estrogen biosynthesis and estrogen metabolism. Our three Specific Aims will include the following: 1) Develop fast liquid chromatography-tandem mass spectrometry analytical methods with improved sensitivity and selectivity for the quantitation of estrogens and their metabolites. The goal is to minimize sample preparation and analysis time and utilize only commercially available derivatization reagents and standard instrumentation. The methods will be validated for the analysis of serum, urine, and cell media samples. 2) Establish in vitro assays for identifying botanical modulations to estrogen biosynthesis and estrogen metabolism. Two cell lines widely used in research laboratories for regulatory purposes will be evaluated for their biological relevance and availability. 3) Quantify estrogens and their metabolites in clinical samples of women taking BDS. This will enable us to determine significant modulations to hormone levels and be used to validate the in vitro assays from Aim 2. Together, the clinical data will answer our hypothesis regarding the importance of estrogen modulation in BDS product safety and mechanism of action, and the validated in vitro assays will provide a fast and accurate preclinical mechanism to assess BDS safety at modest cost.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$5,332 )
2023	2021	OREGON STATE UNIVERSITY	1500 SW JEFFERSON AVE	CORVALLIS	OR	97331	BENTON	USA	Research and Training in Complementary and Integrative Health	001	3	5/15/2023	NON-COMPETING CONTINUATION	-$2,754
2023	2021	OREGON STATE UNIVERSITY	1500 SW JEFFERSON ST	CORVALLIS	OR	97331	BENTON	USA	Research and Training in Complementary and Integrative Health	000	3	3/9/2023	NON-COMPETING CONTINUATION	-$2,578
														Subtotal = -$5,332

Issue Date FY: 2021 ( Subtotal = $21,218 )
2021	2021	OREGON STATE UNIVERSITY	1500 SW JEFFERSON ST	CORVALLIS	OR	97331	BENTON	USA	Research and Training in Complementary and Integrative Health	000	3	7/7/2021	NON-COMPETING CONTINUATION	$21,218
														Subtotal = $21,218

Issue Date FY: 2020 ( Subtotal = $41,443 )
2020	2020	OREGON STATE UNIVERSITY	1500 SW JEFFERSON ST	CORVALLIS	OR	97331	BENTON	USA	Research and Training in Complementary and Integrative Health	000	2	7/1/2020	NON-COMPETING CONTINUATION	$41,443
														Subtotal = $41,443

Issue Date FY: 2019 ( Subtotal = $40,481 )
2019	2019	OREGON STATE UNIVERSITY	1500 SW JEFFERSON ST	CORVALLIS	OR	97331	BENTON	USA	Research and Training in Complementary and Integrative Health	001	1	8/9/2019	NEW	$0
2019	2019	OREGON STATE UNIVERSITY	1500 SW JEFFERSON ST	CORVALLIS	OR	97331	BENTON	USA	Research and Training in Complementary and Integrative Health	000	1	8/9/2019	NEW	$40,481
														Subtotal = $40,481

Grand Total All Awards = $97,810

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Validation of preclinical assays with clinical data to evaluate the safety of estrogenic botanical dietary supplements

Award Number: F31AT010559

ORGANIZATION: CENTER FOR DRUG EVALUATION AND RESEARCH, NIH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer